

**SUBJECT: TRANSENDOSCOPIC THERAPIES
FOR GASTROESOPHAGEAL
REFLUX DISEASE (GERD)**

POLICY NUMBER: 7.01.45

CATEGORY: Technology Assessment

EFFECTIVE DATE: 02/21/01

**REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04,
08/18/05, 06/15/06, 05/17/07, 05/14/08,
05/28/09, 05/27/10**

ARCHIVED DATE: 05/19/11

EDITED DATE: 05/24/12, 05/23/13, 05/22/14

PAGE: 1 OF: 8

- *If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.*
- *Medical policies apply to commercial and Medicaid products only when a contract benefit for the specific service exists.*
- *Medical policies only apply to Medicare products when a contract benefit exists and where there are no National or Local Medicare coverage decisions for the specific service.*

POLICY STATEMENT:

- I. Based upon our criteria and lack of peer-reviewed literature, *transesophageal radiofrequency* applications to the gastroesophageal junction (e.g., Stretta procedure) as a treatment of GERD has not been medically proven to be effective and is therefore considered **investigational**.
- II. Based upon our criteria and lack of peer-reviewed literature, *endoscopic gastroplasty/gastroplication* (e.g., EndoCinch, Sew- Right, Plicator™ System, Syntheon ARD Plicator) as a treatment of GERD has not been medically proven to be effective and is therefore considered **investigational**.
- III. Based upon our criteria and lack of peer-reviewed literature, *endoluminal fundoplication* (e.g., ELF, EsophyX™) or *transoral incisionless fundoplication* (TIF) as a treatment of GERD has not been medically proven to be effective and is therefore considered **investigational**.
- IV. Based upon our criteria and lack of peer-reviewed literature, injection/implantation of biocompatible material (e.g., endoscopic submucosal implantation of Plexiglas beads, Durasphere®, Enteryx or use of the Gatekeeper System) as a treatment of GERD has not been medically proven to be effective and is therefore considered **investigational**.

Refer to Corporate Medical Policy #11.01.03 regarding Experimental and Investigational Services.

POLICY GUIDELINES:

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

Gastroesophageal reflux disease (GERD) is defined as symptoms (e.g., heartburn, regurgitation, pain, and dysphagia) and/or tissue damage that results from the abnormal reflux of gastric contents into the esophagus and can significantly affect the quality of patients' lives. Initial treatment of GERD is geared toward reducing esophageal refluxes via medical therapies (dietary and life style modifications, medications). When standard medical therapies fail, surgery may be considered. The quest for minimally invasive surgical techniques has led to the development of transendoscopic treatments for GERD. Endoscopic therapies can be classified into 3 categories: thermal methods, endoscopic suturing/stapling and injection of implants made up of inert biocompatible material.

The *Stretta* procedure utilizes an endoscope and radiofrequency ablation to create thermal lesions in the submucosa of the gastroesophageal junction. Reduction in reflux is reported to occur due to heat-induced collagen retraction, delayed thermal resorption due to wound healing and afferent nerve pathway disruption at the gastroesophageal junction.

Endoscopic gastroplasty or *gastroplication* involves the suturing of the lower esophageal sphincter to strengthen and lengthen the sphincter in order to reduce reflux. Examples of gastroplication devices include the EndoCinch Suturing Device, the Sew-Right Device®, the Syntheon ARD Plicator and the NDO Plicator™ System.

SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) POLICY NUMBER: 7.01.45 CATEGORY: Technology Assessment	EFFECTIVE DATE: 02/21/01 REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10 ARCHIVED DATE: 05/19/11 EDITED DATE: 05/24/12, 05/23/13, 05/22/14 PAGE: 2 OF: 8
---	--

Another method of endoscopic treatment for GERD is the injection of inert, biocompatible material at or above the cardia. Polymethylmethacrylate (PMMA) or Plexiglas microspheres are injected into the lower esophageal folds. These microspheres, or beads, implant in the submucosa to augment the bulking of tissues and reduce reflux and symptoms of GERD. The Gatekeeper System uses the injection of a hydrogel prosthesis that, once expanded, allows augmentation of the lower esophageal sphincter (LES) by forming a soft pliable lower-esophageal sphincter barrier. Enteryx, a polymer in the form of an injectable solution of ethylene vinyl alcohol that when injected into the LES solidifies into a spongy mass that forms a ring to reduce reflux, is no longer commercially available as treatment for GERD (see rationale statement). Pyrolytic carbon-coated beads (Durasphere®), FDA approved as a submucosal urethral bulking agent, are being investigated in the treatment of mild-moderate GERD due to their success in the treatment of urinary incontinence due to intrinsic bladder deficiency. The beads are injected endoscopically in the region of the gastroesophageal junction (GEJ) with the intent to close/tighten the GEJ lumen .

Endoluminal fundoplication (ELF) is designed to restore the antireflux barrier by recreating the valve at the gastroesophageal junction. The fundoplication device is passed transorally under direct visualization by an endoscope. A proprietary esophageal invaginator incorporated into the device is used to engage the distal esophagus at the level of the Z-line to reduce the hiatal hernia, if present. Gastric tissue from the fundus is then drawn between the body of the device and the tissue mold used to shape each portion of the gastroesophageal valve. Finally, several polypropylene fasteners are delivered across the mold tissue to create a 3-5 cm long serosa-to-serosa flap.

RATIONALE:

The Bard Endocinch Suturing System received 510(k) premarket clearance from the U.S. Food and Drug Administration (FDA) on March 20, 2000. The Stretta System received 510(k) premarket clearance from the FDA on April 18, 2000. Enteryx received FDA clearance on April 22, 2003 for the treatment of patients with GERD who require and respond to proton pump inhibitors (PPIs). In October 2005, in a joint decision by the FDA and Boston Scientific, a voluntary recall was initiated of all Enteryx Procedure Kits and injector products from commercial distribution. This action was initiated by Boston Scientific based upon growing data of serious adverse effects that occurred related to the incorrect transmural injection of the product into vital organs that went unrecognized at the time of the procedure. On April 29, 2003 NDO Surgical announced that it had received clearance from the FDA for the Plicator device for the treatment of GERD. The Sew-Right Device®, the Syntheon ARD Plicator and Plexiglas beads currently does not have FDA approval for use in an anti-reflux application. The Gatekeeper System was actually withdrawn in late 2005 before FDA approval and is not expected to be marketed.

Improvement in the net health outcome has not been proven with transendoscopic techniques in the treatment of GERD. In one study of endoscopic gastroplasty, patients appeared to have marginal GERD problems and it is unlikely that these patients would be candidates for a minimally invasive procedure as a primary course of treatment. Long-term outcomes are not available for any of the procedures.

The effectiveness of transendoscopic treatments for GERD has not been demonstrated outside the investigational setting. There is little published data from controlled studies in peer-reviewed literature in regard to transendoscopic treatments of GERD. Studies performed generally have not been placebo effect controlled. Large scale controlled studies of the three transendoscopic techniques are needed to establish the safety and efficacy of these procedures.

The American College of Gastroenterology provided updated guidelines in January of 2005: There are 3 broad categories of endoscopic therapy: radiofrequency application to the LES area, techniques designed to decrease reflux using endoscopic sewing devices, and techniques using an injection into the LES region. All these techniques seem to produce an improvement in reflux symptoms, although significant changes in lower esophageal sphincter pressure have not been demonstrated and less than 35% of patients have been demonstrated to have normalization of their intraesophageal acid exposure (measured by pH testing). When results of the available studies are critically examined, many issues remain unresolved, including: long-term durability, safety and efficacy of these procedures performed outside of clinical trials and efficacy in atypical presentations of GERD, among others. Systematic reviews were unable to identify any clear

SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) POLICY NUMBER: 7.01.45 CATEGORY: Technology Assessment	EFFECTIVE DATE: 02/21/01 REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10 ARCHIVED DATE: 05/19/11 EDITED DATE: 05/24/12, 05/23/13, 05/22/14 PAGE: 3 OF: 8
---	--

indications for these techniques, but did support their use in clinical trials and outside clinical trials in certain well-informed patients who have well documented GERD that is responsive to PPI therapy.

EsophyX™ (EndoGastric Solutions, Inc), an endoluminal fundoplication device, received FDA clearance September 2007. The 2006 Society of American Gastrointestinal Surgeons (SAGES) national meeting was the stage for several presentations describing ELF. The clinical data presented was from 17 GERD patients referred for laparoscopic surgery who were treated with an ELF procedure instead. GERD-HRQL scores at three months post-treatment improved 53% and PPI use was eliminated in 15 of 17 subjects at a mean of 5.5 months after the intervention. Importantly, the investigators (Cadiere, Rajan) reported that the pH scores reflecting distal esophageal acid exposure normalized in 10 of 11 treated patients studied at three months. Adverse events included moderate throat irritation and epigastric pain, resolving within one week, with one admission for pain assessment with spontaneous resolution without determined cause. Further investigations are in progress; long-term outcomes data and a sham-controlled study are necessary to determine its efficacy and safety as a technique for the treatment of GERD.

CODES: Number Description

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

CPT: 43257 (E/I) Upper gastrointestinal endoscopy including esophagus, stomach and either duodenum and/or jejunum as appropriate; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease

Copyright© 2014 American Medical Association, Chicago, IL

HCPCS: C9724 (E/I) Endoscopic full thickness plication of stomach using endoscopic plication system (EPS); includes endoscopy

ICD9: 530.81 Esophageal reflux

530.11 Reflux esophagitis

ICD10: K21.0 Gastro-esophageal reflux disease with esophagitis

K21.9 Gastro-esophageal reflux disease without esophagitis

REFERENCES:

*Abou-Rebyeh H, et al. Long-term failure of endoscopic suturing in the treatment of gastroesophageal reflux: a prospective follow-up study. *Endoscopy* 2005 Mar;37(3):213-6.

American College Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2013 Mar [<http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/>] accessed 4/16/13.

American Gastroenterological Association. AGA Institute medical position statement on the management of gastroesophageal reflux disease. 2008 [<http://www.gastro.org>] accessed 4/17/13.

*Arts J, et al. A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. *Dig Dis Sci* 2005 Feb;50(2):351-6.

Aziz A, et al. A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. *Surg Endosc* 2009 Sep 3 [Epub ahead of print].

Barnes WE, et al. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in Community Practice. *Surg Innov* 2011 Feb 22 [Epub ahead of print].

SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) POLICY NUMBER: 7.01.45 CATEGORY: Technology Assessment	EFFECTIVE DATE: 02/21/01 REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10 ARCHIVED DATE: 05/19/11 EDITED DATE: 05/24/12, 05/23/13, 05/22/14 PAGE: 4 OF: 8
---	--

Bell RC, et al. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc 2010 Dec 8 [Epub ahead of print].

Bergman S, et al. Endoluminal fundoplication with ExophyX: the initial North American experience. Surg Innov 2008 Sep;15(3):166-70.

Birk J, et al. The Plicator procedure for the treatment of gastroesophageal reflux disease: a registry study. Surg Endosc 2009;23(2):423-31.

BlueCross BlueShield Association. Transendoscopic therapies for gastroesophageal reflux disease. Medical Policy Reference Manual Policy #2.01.38. 2013 Nov 14.

*BlueCross BlueShield Association Technology Evaluation Center (TEC). Transesophageal endoscopic treatments for gastroesophageal reflux disease. 2004 Feb;18(20).

Cadiere GB, et al. Endoluminal fundoplication (ELF)- evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol 2006 Dec;15(6):348-55.

Cadiere GB, et al. Endoluminal fundoplication by a transoral device for the treatment of GERD: A feasibility study. Surg Endosc 2008 Feb;22(2):333-42.

Cadiere GB, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12 month results of a prospective multicenter study. World J Surg 2008 Aug;32(8):1676-88.

Cadiere GB, et al. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc 2009 Mar 14 [Epub ahead of print].

Cassare JE, et al. Endoscopic anti-reflux devices: a year of challenges and change. Curr Opin Gastroenterol 2006 Jul;22(4):423-8.

*Chadalavada R, et al. Comparative results of endoluminal gastroplasty and laparoscopic antireflux surgery for the treatment of GERD. Surg Endosc 2004 Feb; 18(2):261-5.

Chen D, et al. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 2009 Feb;96(2):128-36.

*Cipolletta L, et al. Delivery of radiofrequency energy to the gastroesophageal junction (Stretta procedure) for the treatment of gastroesophageal reflux disease. Surg Endosc 2005 May 3.

*Cohen LB, et al. Enteryx implantation for GERD: expanded multicenter trial results and interim post approval follow-up to 24 months. Gastrointest Endosc 2005 May;61(6):650-8.

Comay D, et al. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost effectiveness analysis. Can J Gastroenterol 2008 Jun;22(6):552-8.

Coron E, et al. Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2008 Nov 1;28(9):1147-58.

Demyttenaere SV, et al. Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 2010 Apr;24(4):854-8.

*DeVault KR, American College of gastroenterology, et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan;100(1):190-200.

*Deviere J, et al. Endoscopic implantation of a bio-polymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study. Gastrointest Endosc 2002 Mar;55(3):335-41.

*Deviere J, et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterol 2005 Mar;128(3):532-40.

SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) POLICY NUMBER: 7.01.45 CATEGORY: Technology Assessment	EFFECTIVE DATE: 02/21/01 REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10 ARCHIVED DATE: 05/19/11 EDITED DATE: 05/24/12, 05/23/13, 05/22/14 PAGE: 5 OF: 8
---	--

*DiBaise JK, et al. Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. Am J Gastroenterol 2002 Apr;97(4):833-42.

Domagk D, et al. Endoluminal gastroplasty (EndoCinch) versus endoscopic polymer implantation (Enteryx) for treatment of gastroesophageal reflux disease: 6-month results of a prospective, randomized trial. Am J Gastroenterol 2006 Mar;101(3):422-30.

Dundon JM, et al. Radiofrequency energy delivery to the lower esophageal sphincter (Stretta procedure) does not provide long-term symptom control. Surg Innov 2008 Dec;15(4):297-301.

Eckardt AJ, et al. Antireflux 'barriers': problems with patient recruitment for a new endoscopic antireflux procedure. Eur Gastroenterol Hepatol 2009 Mar 18 [Epub ahead of print].

Falk GW, et al. AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterol 2006 Oct;131(4):1315-36.

*Feretis C, et al. Endoscopic implantation of plexiglas (PMMA) microspheres for the treatment of GERD. Gastrointest Endosc 2001 Apr;53(4):423-6.

*Filipi CJ, et al. Transoral endoscopic suturing for gastroesophageal reflux disease: a multicenter trial. Gastrointest Endosc 2001 Apr;53(4):416-22.

*Fockens P, et al. Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: multicenter study of the gatekeeper reflux repair system. Endosc 2004 Aug;36(8):682-9.

Fockens P, et al. Prospective randomized controlled trial of an injectable esophageal prosthesis versus a sham procedure for endoscopic treatment of gastroesophageal reflux disease. Surg Endosc 2010 Mar 3 [Epub ahead of print].

Fry LC, et al. Systematic review: endoluminal therapy for gastro-oesophageal reflux disease: evidence from clinical trials. Eur J Gastroenterol Hepatol 2007 Dec;19(12):1125-39.

Ganz RA, et al. A new injectable agent for the treatment of GERD: results of the Durasphere pilot trial. Gastrointest Endosc 2009 Feb;69(2):318-23.

*Go MR, et al. Delivery of radiofrequency energy to the lower esophageal sphincter improves symptoms of gastroesophageal reflux. Surg 2004 Oct;136(4):786-94.

Hoppo T, et al. Transoral incisionless fundoplication 2.0 procedure using EsophyX™ for gastroesophageal reflux disease. J Gastrointest Surg 2010 Dec;14(12):1891-5.

Iqbal A, et al. Endoscopic therapies of gastroesophageal reflux disease. World J Gastroenterol 2006 May 7;12 (17):2641-55.

Jafri SM, et al. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol 2009 Jul;25(4):352-7.

Kahrilas PJ, et al. American Gastroenterological Association. American Gastroenterological Association Institute Technical Review on the management of gastroesophageal reflux disease. Gastroenterol 2008 Oct;135(4):1392-413.

Kahrilas PJ, et al. American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterol 2008 Oct;135(4):1383-91.

*Lehman G. Endoscopic and endoluminal techniques for control of gastroesophageal reflux: are they ready for widespread clinical applications?. Gastrointest Endosc 2000 Dec;52(6)Pt 1:808-11.

Liao CC, et al. Endoluminal gastroplication for the treatment of gastroesophageal reflux disease: a 2-year prospective pilot study from Taiwan. J Gastroenterol Hepatol 2008 Mar;23(3):398-405.

<p>SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)</p> <p>POLICY NUMBER: 7.01.45</p> <p>CATEGORY: Technology Assessment</p>	<p>EFFECTIVE DATE: 02/21/01</p> <p>REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10</p> <p>ARCHIVED DATE: 05/19/11</p> <p>EDITED DATE: 05/24/12, 05/23/13, 05/22/14</p> <p>PAGE: 6 OF: 8</p>
--	---

*Lufti RE, et al. Three year's experiences with the Stretta procedure: did it really make a difference? Surg Endosc 2005 Feb;19(2):289-95.

Mahmood Z, et al. Comparison of transesophageal endoscopic placation (TEP) with laparoscopic Nissen fundoplication (LNF) in the treatment of uncomplicated reflux disease. Am J Gastroenterol 2006 Mar;101(3):431-6.

Malik A, et al. Endoluminal and transluminal surgery: current status and future possibilities. Surg Endosc 2006 Aug;20(8):1179-92.

Mattar SG, et al. Treatment of refractory gastroesophageal reflux disease with radiofrequency energy (Stretta) in patients after Roux-en-Y gastric bypass. Surg Endosc 2006 Jun;20(6):850-4.

Montgomery M, et al. Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: a randomized, placebo-controlled study. Scand J Gastroenterol 2006 Dec;41(12):1382-9.

Mosler P, et al. Evaluation of supplemental cautery during endoluminal gastroplication for the treatment of gastroesophageal reflux disease. Surg Endosc 2008 Oct;22(10):2158-63.

National Institute for Health and Clinical Excellence (NICE). Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. Issue date Mar 2009 [NICE.org] accessed 4/17/11.

Noar MD, et al. Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure. Gastrointest Endosc 2007 Mar;65(3):367-72.

Pleskow D, et al. Endoscopic full-thickness placation for the treatment of GERD: long-term multicenter results. Surg Endosc 2007 Mar;21(3):439-44.

*Pleskow D, et al. Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc 2005 May;61(6):643-9.

Pleskow D, et al. Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. Surg Endosc 2007 Mar;21(3):439-44.

Pleskow D, et al. Endoscopic full thickness plication for the treatment of GERD: Five-year long-term multi-center results. Surg Endosc 2008 Feb;22(2):326-32.

Ramage JI, et al. Endoscopically placed titanium plicator for GERD: Pivotal phase- preliminary 6-months results. Gastrointest Endosc 2006 Apr;63(5):AB126.

Repici A, et al. Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. J Gastrointest Surg 2010 Jan;14(1):1-6.

Reymunde A, et al. Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up. Gastrointest Endosc 2007 Mar;65(3):361-6.

*Rosen M, et al. Endoscopic therapy for gastroesophageal reflux disease. Semin Laparosc Surg 2001 Sep;8(3):207-17.

Ryou M, et al. Endoscopic therapy for GERD: does it have a future? Curr Gastroenterol Rep 2008 Jun;10(3):215-21.

*Schiefke I, et al. Long-term failure of endoscopic gastroplication (EndoCinch). Gut 2005 Jun;54(6):752-8.

*Schiefke I, et al. Use of an endoscopic suturing device (the "ESD") to treat patients with gastroesophageal reflux disease, after unsuccessful EndoCinch endoluminal gastroplication: another failure. Endoscopy 2005 Aug;37(8):700-5.

*Schumacher B, et al. Reduced medication dependency and improved symptoms and quality of life 12 months after Enteryx implantation for gastroesophageal reflux. J Clin Gastroenterol 2005 Mar;39(3):212-9.

Schwartz MP, et al. Endoscopic gastroplication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trial. Gut 2007 Jan;56(1):20-8.

SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) POLICY NUMBER: 7.01.45 CATEGORY: Technology Assessment	EFFECTIVE DATE: 02/21/01 REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10 ARCHIVED DATE: 05/19/11 EDITED DATE: 05/24/12, 05/23/13, 05/22/14 PAGE: 7 OF: 8
---	--

Sgouros SN, et al. Endoscopic therapy for gastroesophageal reflux disease: a systematic review. *Digestion* 2006;74(1):1-14.

Testoni PA, et al. Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. *World J Surg* 2010 Apr;34(4):750-7.

Thomson M, et al. Medium-term outcome of endoluminal gastroplication with EndoCinch device in children. *J Pediatr Gastroenterol Nutr* 2008 Feb;46(2):172-7.

*Torquati A, et al. Long-term follow-up study of the Stretta procedure for the treatment of gastroesophageal reflux disease. *Surg Endosc* 2004 Oct;18(10):1475-9.

*Triadafilopoulos G, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. *Gastrointest Endosc* 2001 Apr;53(4):407-15.

*Triadafilopoulos G, et al. The Stretta procedure for the treatment of GERD 6 and 12 month follow-up of the US open label trial. *Gastrointest Endosc* 2002 Feb;55(2):149-56.

U.S. Department of Health and Human Services Agency for Health Research and Quality. Comparative effectiveness of management strategies for gastroesophageal reflux disease.

[<http://effectivehealthcare.ahrq.gov/synthesize/reports/finalGERD.cfm>] accessed 4/17/11.

*Velanovich V, et al. Case-control comparison of endoscopic gastroplication with laparoscopic fundoplication in the management of gastroesophageal reflux disease: early symptomatic outcomes. *Surg Laparosc Endosc Percutan Tech* 2002 Aug;12(4):219-23.

von Rentein D, et al. Endoscopic full-thickness plication (Plicator) with two serially placed implants improves esophagitis and reduces PPI use and esophageal acid exposure. *Endoscopy* 2008 Mar;40(3):173-8.

Von Rentein D, et al. Endoscopic full-thickness placation for the treatment of GERD by application of multiple Plicator implants: a multicenter study (with video). *Gastrointest Endosc* 2008 Nov;68(5):833-44.

Von Rentein D, et al. Endoscopic full-thickness placation for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results. *Surg Endosc* 2009 Aug;23(8):1866-75.

*Watson TJ, et al. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease. *Thorac Surg Clin* 2005 Aug;15(3):405-15.

*Wolfsen HC, et al. The Stretta procedure for the treatment of GERD: a registry of 558 patients. *J Laparosc Adv Surg Tech A* 2002 Dec;12(6):395-402.

Zagol B, et al. Advances in transoral fundoplication for oesophageal reflux. *Dig Liver Dis* 2011 Mar 5 [Epub ahead of print].

* key article

KEY WORDS:

ELF, Endocinch, endoluminal fundoplication, Enteryx, EsophyX, Gastroplication, Gatekeeper, NDO Plicator System, Stretta.

SUBJECT: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)	EFFECTIVE DATE: 02/21/01 REVISED DATE: 02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10 ARCHIVED DATE: 05/19/11 EDITED DATE: 05/24/12, 05/23/13, 05/22/14 PAGE: 8 OF: 8
POLICY NUMBER: 7.01.45 CATEGORY: Technology Assessment	

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a Local Coverage Determination (LCD) and Article for endoscopic treatment of GERD (L33371).

Please refer to the following LCD website for Medicare Members:

[http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33371&ContrId=179&ver=12&ContrVer=1&DocType=Active&Cntrctr=140&name=CGS+Administrators%2c+LLC+\(18003%2c+DME+MAC\)&DocStatus=Future&CntrctrSelected=140*2&LCntrctr=140*2&bc=AgIAAAAAAAA%3d%3d&](http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33371&ContrId=179&ver=12&ContrVer=1&DocType=Active&Cntrctr=140&name=CGS+Administrators%2c+LLC+(18003%2c+DME+MAC)&DocStatus=Future&CntrctrSelected=140*2&LCntrctr=140*2&bc=AgIAAAAAAAA%3d%3d&)